Germany’s Merck Announces $11.3 Billion Acquisition of U.S.-Based Bio-Techne
German pharmaceutical giant Merck KGaA has agreed to acquire life sciences company Bio-Techne for approximately $11.3 billion in a cash deal, marking one of the largest transactions in the sector this year. The acquisition aims to strengthen Merck's position in drug discovery tools and biopharmaceutical manufacturing support.